title: From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.
abstract: One of the biggest challenges in the development of therapeutics for central nervous system (CNS) disorders is achieving sufficient blood-brain barrier (BBB) penetration. Research in the past few decades has revealed that the BBB is not only a substantial barrier for drug delivery to the CNS but also a complex, dynamic interface that adapts to the needs of the CNS, responds to physiological changes, and is affected by and can even promote disease. This complexity confounds simple strategies for drug delivery to the CNS, but provides a wealth of opportunities and approaches for drug development. Here, I review some of the most important areas that have recently redefined the BBB and discuss how they can be applied to the development of CNS therapeutics.
authors.affiliation: Veterans Affairs Puget Sound Health Care System, Geriatrics Research Education and Clinical Center and Department of Medicine, University of Washington School of Medicine, Division of Gerontology and Geriatric Medicine, 1660 South Columbian Way, Seattle, Washington 98108, USA.
authors.forename: William A
authors.initials: WA
authors.lastname: Banks
mesh_terms: D001692:Biological Transport / Q000187:drug effects; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D002491:Central Nervous System Agents / Q000494:pharmacology*; D002493:Central Nervous System Diseases / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D054539:Medication Therapy Management
chemical_list: D002491:Central Nervous System Agents